- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1414854-42-4] Verosudil
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16758 |
| Brand: | MCE |
| CAS: | 1414854-42-4 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 327.40 |
| Molecular Formula | C17H17N3O2S |
| SMILES | O=C(NC1=CC2=C(C(NC=C2)=O)C=C1)C(N(C)C)C3=CSC=C3 |
Summary
IC50 & Target
|
ROCK1 2 nM (Ki) |
ROCK2 2 nM (Ki) |
PKA 69 nM (Ki) |
MRCKA 28 nM (Ki) |
CAM2A 5855 nM (Ki) |
PKC theta 9322 nM (Ki) |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01302249 | Aerie Pharmaceuticals |
Glaucoma|Ocular Hypertension
|
February 2011 | Phase 2 |
| NCT01699464 | Aerie Pharmaceuticals |
Ocular Hypertension|Open-angle Glaucoma
|
October 2012 | Phase 2 |
| NCT01474135 | Aerie Pharmaceuticals |
Glaucoma|Ocular Hypertension
|
December 2011 | Phase 2 |
| NCT01789736 | Aerie Pharmaceuticals |
Open Angle Glaucoma|Ocular Hypertension
|
February 2013 | Phase 2 |
| NCT00902200 | Aerie Pharmaceuticals |
Elevated Intraocular Pressure
|
May 2009 | Phase 2 |
| NCT01936389 | Robert Ritch, MD, LLC. |
Exfoliation Syndrome|Ocular Hypertension|Open Angle Glaucoma
|
September 2013 | Phase 2 |
| NCT01250197 | Aerie Pharmaceuticals |
Normal Volunteers
|
November 2010 | Phase 1 |
| NCT01330979 | Aerie Pharmaceuticals |
Open Angle Glaucoma|Ocular Hypertension
|
May 2011 | Phase 2 |
| NCT02174991 | New York Glaucoma Research Institute |
Glaucoma
|
June 2014 | Phase 2 |
| NCT01060579 | Aerie Pharmaceuticals |
Glaucoma
|
February 2010 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 16.67 mg/mL ( 50.92 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.0544 mL | 15.2718 mL | 30.5437 mL |
| 5 mM | 0.6109 mL | 3.0544 mL | 6.1087 mL |
| 10 mM | 0.3054 mL | 1.5272 mL | 3.0544 mL |
References
- [1] Lin CW, Sherman B, Moore LA, et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther. 2018;34(1-2):40‐51.
- [2] Kopczynski C, Novack GD, Swearingen D, van Haarlem T. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers. Br J Ophthalmol. 2013;97(5):567‐572.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.